shares of bristol myers squibb bmy were up 12 in premarket trading on wednesday the day after the company shared betterthanexpected results for the third quarter of the year bristol had earnings of 16 billion or 75 cents per share in the third quarter of 2022 up from 15 billion or 69 cents per share in the same quarter in 2021 adjusted earnings per share were 199 against a factset consensus of 183 the drug maker reported revenue of 112 billion in the third quarter of the year down from 116 billion in the same three months of last year the factset consensus was 112 billion bristol attributed the revenue slide to foreignexchange impacts and declining sales of its cancerdrug revlimid as generic versions of the drug have come to market the drug brought in 24 billion in revenue for the quarter down from 33 billion in the same quarter a year ago the bloodthinner eliquis continues to be one of bristols leading therapies generating 26 billion in sales the company reiterated guidance for the year saying it still expects eps of 774 to 774 in 2022 bristols stock has gained 167 this year while the broader sp 500 spx has declined 190